| Drug Name |
Cefadroxil monohydrate |
| Drug ID |
BADD_D00381 |
| Description |
Long-acting, broad-spectrum, water-soluble, cephalexin derivative. |
| Indications and Usage |
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes |
| Marketing Status |
approved; vet_approved; withdrawn |
| ATC Code |
J01DB05 |
| DrugBank ID |
DB01140
|
| KEGG ID |
D02353
|
| MeSH ID |
D002434
|
| PubChem ID |
47964
|
| TTD Drug ID |
D0X9ZC
|
| NDC Product Code |
61303-111; 61303-715; 52946-0903 |
| UNII |
280111G160
|
| Synonyms |
Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate |
